Onyx Pharma, Bayer Have Yet to Prove Utility of Cancer Drug

ByBiomed Group:Onyx Pharmaceuticals (ONXX) is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of cancer.

By Markus Aarnio:Onyx Pharmaceuticals (ONXX) is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. The company is focused on developing novel medicines that target key molecular pathways.I see at least 3 reasons to buy the company: 1. Promising pipeline

Zacks.com submits: Onyx Pharmaceuticals Inc.’s (ONXX) first quarter 2011 loss of 31 cents per share was a couple of cents wider than the Zacks Consensus Estimate and 21 cents wider than the year-ago loss. Despite an increase in revenues, higher operating expenses led to the wider loss. Quarterly Details

Zacks.com submits: We have upgraded our rating on Onyx Pharmaceuticals, Inc. (ONXX) to Neutral from Underperform following the release of fourth quarter and fiscal year 2010 financial results. We were pleased to see an improvement in Nexavar sales.

By Brian L. Wilson:After a choppy and relatively bearish 2013, the cancer drug company Onyx Pharmaceuticals (NASDAQ: ONXX) is once again on the rise after the FDA approved the drug Stivarga (regorafenib) on February 25th, 2013 for the gastrointestinal stromal tumor (GIST) indication in patients who have previously been treated with imatinib mesylate and sunitinib malate.

By William Meyers: Many, but not all, analysts had a dim view of Onyx Pharmaceuticals (ONXX) at the beginning of 2012. Onyx had only one approved therapy, Nexavar for liver and kidney cancer. Between sharing Nexavar revenues with marketing partner Bayer and heavy R&D spending on new drugs and indications, Onyx ended in the red in most quarters.

EP Vantage submits:Another weak quarter for kidney and liver cancer treatment Nexavar prompted a 5% drop in Onyx Pharmaceuticals’ (ONXX) shares Thursday and questions about what exactly is driving the disappointing figures.

By Ed Liston: This year, a number of cancer drugs have received the FDA approval. In October 2012, the FDA approved Abraxane for the treatment of non-small cell lung cancer. Abraxane is marketed by Celgene (CELG).